Volume 5, Issue 1 (Winter-Spring 2022)
Mod Med Lab J 2022, 5(1): 29-37 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Nabavi S M, Mehrabani M, Karimi S, Mohammadianinejad E, Ghafari M, Dastoorpoor M. COVID-19 vaccination in patients with Multiple Sclerosis: A Practical guide for Neurologists. Mod Med Lab J 2022; 5 (1) :29-37
URL: http://modernmedlab.com/article-1-113-en.html
URL: http://modernmedlab.com/article-1-113-en.html
Seyed Massood Nabavi 
, Mehrnoosh Mehrabani , Shahedeh Karimi , Ehsan Mohammadianinejad , Mehran Ghafari , Maryam Dastoorpoor
, Mehrnoosh Mehrabani , Shahedeh Karimi , Ehsan Mohammadianinejad , Mehran Ghafari , Maryam Dastoorpoor
Abstract: (1226 Views)
Coronavirus disease 2019 (COVID-19) is more common in patients with multiple sclerosis because of receiving immunosuppressive or immunomodulating disease-modifying therapies (DMTs). On the other hand, some of these drugs may interact on COVID-19 vaccines. In this commentary, first we introduce some available COVID-19 vaccines and then discuss the effect of different DMTs on immune responses after vaccination. We have not found a connection between vaccination and MS relapses, so we suggest that the benefit from the vaccine outweighs any potential risks in these patients.
Keywords: Coronavirus disease 2019 (COVID-19), Multiple sclerosis, Vaccination, Disease-modifying therapies (DMTs)
Type of Study: Review Article |
Subject:
Medical Sciences
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
